1197-21-3

Basic information

• Product Name: PHENTERMINE HYDROCHLORIDE
• Synonyms: 1-phenyl-2-methyl-2-aminopropanehydrochloride;alpha,alpha-dimethyl-phenethylaminhydrochloride;alpha-methylamphetaminehydrochloride;benzeneethanamine,alpha,alpha-dimethyl,hydrochloride;phenyl-t-butylaminehydrochloride;wilpohydrochloride;PHENTERMINE HYDROCHLORIDE;ALPHA,ALPHA-DIMETHYLPHENETHYLAMINE HYDROCHLORIDE
• CAS NO: 1197-21-3
• Molecular Formula: C₁₀H₁₆N*Cl
• Molecular Weight: 185.69
• EINECS: 214-821-9
• Product Categories: Aminomethyl's;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het;Amines;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 1197-21-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 200-201℃
• Boiling Point: 206 °C at 760 mmHg
• Flash Point: 93.1 °C
• Appearance: /
• Vapor Pressure: 0.243mmHg at 25°C
• Merck: 13,7346
• CAS DataBase Reference: PHENTERMINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: PHENTERMINE HYDROCHLORIDE(1197-21-3)
• EPA Substance Registry System: PHENTERMINE HYDROCHLORIDE(1197-21-3)

Safety Data

• Hazard Codes: T,Xi
• Statements: 25
• Safety Statements: 22-26-36/37-45
• RIDADR: UN 2811 6.1/PG 3
• WGK Germany: 3
• RTECS: SH4950000
• Hazardous Substances Data: 1197-21-3(Hazardous Substances Data)

Usage

Description

Phentermine Hydrochloride is a synthetic medication that belongs to the amphetamine class of drugs. It is a central nervous system stimulant and is primarily used as an anorexic agent to suppress appetite. As a white solid, it is chemically derived and has been formulated for pharmaceutical applications.

Uses

Used in Pharmaceutical Industry:
Phentermine Hydrochloride is used as a controlled substance for its stimulant properties, specifically to treat obesity. It functions as an anorexic agent, helping to reduce appetite and promote weight loss in individuals struggling with obesity. The drug is also used in combination with diet and exercise to manage weight in patients with certain health conditions.
Additionally, Phentermine Hydrochloride is used as an appetite suppressant in the weight management industry, where it is prescribed to individuals who require short-term assistance in controlling their food intake.

Therapeutic Function

Antiobesity

InChI:InChI=1/C10H15N.ClH/c1-10(2,11)8-9-6-4-3-5-7-9;/h3-7H,8,11H2,1-2H3;1H

Upstream product

• 5531-33-9 N-(2-methyl-1-phenylpropan-2-yl)acetamide 
• 97847-79-5 C₂₂H₂₄NOP 
• 83386-09-8 2-azido-2-methyl-3-phenylpropane 
• 100-39-0 benzyl bromide 
• 1754-74-1 2-chloro-2-methyl-1-phenylpropane 
• 100-86-7 2-Methyl-1-phenyl-2-propanol 
• 6921-34-2 benzylmagnesium chloride 
• 122-09-8 Phentermin 
• 53478-07-2 3-benzyloxy-5-carboxyphenylglyoxal 
• 5669-14-7 2,2-dimethyl-3-phenylpropanoic acid 

Downstream Products

• 108835-36-5 2-amino-2-methyl-1-(4-nitrophenyl)propane sulfate 
• 122-09-8 Phentermin 
• 110871-36-8 4-methyl-N-(2-methyl-1-phenylpropan-2-yl)benzenesulfonamide 
• 61765-66-0 N-(2-methyl-1-phenylpropan-2-yl)-1-phenylmethanimine 
• 64196-24-3 benzyl-(1,1-dimethyl-2-phenyl-ethyl)-amine 
• 731749-75-0 (1,1-dimethyl-2-phenyl-ethyl)-(4-methoxy-benzyl)-amine 
• 28460-55-1 3,3-dimethyl-3,4-dihydroisoquinoline 
• 28459-83-8 3,3-dimethyl-1,2,3,4-tetrahydroisoquinoline 
• 200631-40-9 3,3-dimethyl-2-tosyl-1,2,3,4-tetrahydroisoquinoline 
• 51131-55-6 4-(β-amino-isobutyl)-aniline 
• 96684-29-6 2-amino-2-methyl-1-(4-iodophenyl)propane 
• 128232-09-7 8-Benzyloxy-5-{1-hydroxy-2-[2-(4-iodo-phenyl)-1,1-dimethyl-ethylamino]-ethyl}-1H-quinolin-2-one 
• 128232-11-1 5-<2-<<1-(4-iodophenyl)-2-methylprop-2-yl>amino>-1-hydroxyethyl>-8-hydroxycarbostyril 

Relevant articles and documents

CHEMICAL COMPOUNDS

The invention is directed to 6-(4-pyι?midinyl)-1 H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1 - R4 are defined herein. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic beta cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

Azo Anions in Synthesis: α-Amino Carbanion Equivalents from t-Butyldiphenylmethylhydrazones

α-Amino carbanion equivalents (=C(1-)NH2) and α-hydrazino anion equivalents (=C(1-)NHNH2) are readily accessible from the C-alkylation products of t-butyldiphenylmethylhydrazones; these azoalkanes can be efficiently transformed into amines, hydrazines, and also alkanes under mild reaction conditions.